<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374540</url>
  </required_header>
  <id_info>
    <org_study_id>19859</org_study_id>
    <nct_id>NCT03374540</nct_id>
  </id_info>
  <brief_title>Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients</brief_title>
  <official_title>Comparative Effectiveness of Rivaroxaban and Warfarin for Stroke Prevention in Multi-morbid Patients With Nonvalvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study was to evaluate the comparative safety and effectiveness of&#xD;
      rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular&#xD;
      atrial fibrillation (NVAF) across risk profiles and comorbidities that reflect everyday&#xD;
      clinical practice.&#xD;
&#xD;
      The primary objective in this study was to evaluate the combined end point of stroke or&#xD;
      systemic embolism (SSE), and major bleeding in NVAF patients treated with rivaroxaban vs.&#xD;
      VKA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke or systemic embolism (SSE)</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
    <description>Without access to clinical information and event adjudication in administrative claims data, major bleeding will operationalized as hospital-related bleeding using a clinically validated algorithm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subtypes of major bleeding</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs)</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal impairment</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">78517</enrollment>
  <condition>Nonvalvular Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>Patients who initiated Oral anticoagulant (OAC) treatment with rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K antagonist (VKA)</arm_group_label>
    <description>Patients who initiated OAC treatment with VKA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>15/20 mg</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K antagonist (VKA)</intervention_name>
    <description>Individually adjusted dose</description>
    <arm_group_label>Vitamin K antagonist (VKA)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The source population of this study will be all the insured individuals included in the&#xD;
        Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases (Truven&#xD;
        MarketScan).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be oral anticoagulant naive during the 365 days before the day of the first qualifying&#xD;
             oral anticoagulant (rivaroxaban or VKA) dispensing, and&#xD;
&#xD;
          -  Have â‰¥365 days of continuous medical and prescription coverage before initiation of&#xD;
             oral anticoagulation (which serves as the study's baseline period)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years of age&#xD;
&#xD;
          -  &lt;2 International Classification of Diseases, Ninth/Tenth Revision, Clinical&#xD;
             Modification diagnosis codes for atrial fibrillation&#xD;
&#xD;
          -  Valvular heart disease&#xD;
&#xD;
          -  Transient cause of NVAF&#xD;
&#xD;
          -  Venous thromboembolism&#xD;
&#xD;
          -  Hip or knee arthroplasty&#xD;
&#xD;
          -  Malignant cancer&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  &gt;1 oral anticoagulant prescribed (on index date)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases</name>
      <address>
        <city>Multiple Locations</city>
        <state>Washington</state>
        <zip>20001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <results_reference>
    <citation>Coleman CI, Kreutz R, Sood N, Bunz TJ, Meinecke AK, Eriksson D, Baker WL. Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619868535. doi: 10.1177/1076029619868535.</citation>
    <PMID>31392894</PMID>
  </results_reference>
  <results_reference>
    <citation>Martinez BK, Baker WL, Sood NA, Bunz TJ, Meinecke AK, Eriksson D, Coleman CI. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. Pharmacotherapy. 2019 Feb;39(2):196-203. doi: 10.1002/phar.2213. Epub 2019 Jan 28.</citation>
    <PMID>30597611</PMID>
  </results_reference>
  <results_reference>
    <citation>Baker WL, Beyer-Westendorf J, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. Diabetes Obes Metab. 2019 Sep;21(9):2107-2114. doi: 10.1111/dom.13787. Epub 2019 Jun 11.</citation>
    <PMID>31099460</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernandez AV, Bradley G, Khan M, Fratoni A, Gasparini A, Roman YM, Bunz TJ, Eriksson D, Meinecke AK, Coleman CI. Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. Eur Heart J Qual Care Clin Outcomes. 2020 Oct 1;6(4):301-307. doi: 10.1093/ehjqcco/qcz047.</citation>
    <PMID>31432074</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

